




Editorial

Celebration and Acknowledgment at a Time of Transition

I am far enough along in my career and life to have experienced several different phases and life transitions. When we are young, there are natural starts and finishes associated with high school, college, professional school, and postgraduate training. At each of these finishes, we celebrate with a graduation and great pomp and circumstance. As we get older, the starts and finishes become blurry, and changes in roles and responsibilities overlap. I have always been a believer that we should pause at these inflection points and celebrate the progress made, thank those who helped us on the journey, and admire the new opportunities the future will bring. For the past 7 years I have been a member of the *Clinical Therapeutics* team, the first 5 as the Infectious Diseases Topic Editor and the last 2 as a Co-Editor-in-Chief. I now find myself at one of those transitional moments, as later this month I will be leaving my role at *Clinical Therapeutics*. I wanted to take this opportunity to share with all of you a celebration of the progress we have made and to thank those who have helped me along the way.



In the field of infectious diseases, the past 7 years have been marked by one outbreak after another. In my first year as Topic Editor, we were grappling with *Ebola* and *Enterovirus-D68*, and these topics were included in my first specialty update.^{1,2} Soon thereafter, we dealt with a global *Zika* outbreak (also covered in an update) and obviously the past 2 years have seen our entire way of life turned upside down by the SARS-CoV-2 pandemic.³⁻⁶ Aside from the outbreaks and pandemics, I had the opportunity to organize specialty updates (<https://www.clinicaltherapeutics.com/content/SpecialFocus>) and write many articles on a variety of topics across the entire field of infectious diseases: vaccines, viral infections, the host-pathogen relationship, antimicrobial resistance, and pharmacokinetics in special populations.^{7,8} I have so appreciated the forum that *Clinical Therapeutics* gave me to shed light on so many issues that I thought were important and felt passionate about. I have always valued that *Clinical Therapeutics* is a multidisciplinary journal that often allows papers and projects that do not fit neatly into any one discipline to find a home and an audience. At the outset of 2020, I was fortunate to have been asked to step in to one of the Co-Editor-in-Chief positions along with Jill Maron. Just as we were getting used to the roles and responsibilities, along came COVID-19, which required us to adjust how we ran the journal. We successfully managed the dramatic increase in submissions and contributed several important papers sharing the latest information on COVID-19 infection and vaccines.⁴⁻⁶ We were also able to start a new category of article, our Conversations with the Editors, which has allowed us to capture the thoughts of experts in an informal, efficient, and interactive format.⁹⁻¹⁴ In sync with broader changes happening in our society, we have worked to improve the gender and racial/ethnic diversity of our editorial team.¹⁵ I am proud of what we have accomplished in the past 2 years and think that *Clinical Therapeutics* is in a great position heading into the future.

I want to also take a moment to acknowledge those who have helped me make this journey a fruitful one. I have been lucky to work with a terrific team at *Clinical Therapeutics* and have enjoyed their unwavering support over the past 7 years. Thanks to Jill Maron, my Co-Editor-in-Chief for the past 2 years, for being a terrific partner as we navigated learning how to share the responsibilities together. I am confident the journal will continue to thrive with her leadership. Thanks to Judy Pachella, our Managing Editor, who has been with the team longer than my 7 years, for being a steady and supportive presence, not just for me but also for our entire editorial team. Thanks to Scott Whitener and Riccardo Paracampo, our current Publisher and Scientific Editor, for their help since they joined the team. I also want to acknowledge two former members of our team, Terry Materese and Stefanie Bronson, who played key roles for me as a Topic Editor and then in my transition to Co-Editor-in-Chief. Finally, I would like to thank our readers. Every month, we try to put together the best collection of articles and look forward to your

feedback about the value of that information. I have always cherished that purpose and done my best to give you our best.

While I am transitioning out of the Co-Editor-in-Chief role, I will maintain a relationship with *Clinical Therapeutics* in an emeritus role. This will allow me to stay in touch and periodically contribute in the future. As I look toward the next phase, I celebrate how rich and rewarding this phase at *Clinical Therapeutics* has been.

Ravi Jhaveri, MD

Division of Pediatric Infectious Diseases, Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University Feinberg School of Medicine, Chicago, Illinois

E-mail address: ravi.jhaveri@northwestern.edu

REFERENCES

1. Fischer 2nd WA, Weber D, Wohl DA. Personal protective equipment: protecting health care providers in an *Ebola* outbreak. *Clin Ther.* 2015;37:2402–2410.
2. Schuster JE, Newland JG. Management of the 2014 *Enterovirus* 68 outbreak at a pediatric tertiary care center. *Clin Ther.* 2015;37:2411–2418.
3. Collins MH, Metz SW. Progress and works in progress: update on *Flavivirus* vaccine development. *Clin Ther.* 2017;39:1519–1536.
4. Jhaveri R. Echoes of 2009 H1N1 influenza pandemic in the COVID pandemic. *Clin Ther.* 2020;42:736–740.
5. Jhaveri R. The COVID-19 mRNA vaccines and the pandemic: do they represent the beginning of the end or the end of the beginning? *Clin Ther.* 2021;43:549–556.
6. Jhaveri R. The next set of COVID-19 vaccines: leveraging new development platforms to increase access for more people around the world. *Clin Ther.* 2021;43:702–710.
7. Espinosa C, Jhaveri R, Barritt ASt. Unique challenges of hepatitis C in infants, children, and adolescents. *Clin Ther.* 2018;40:1299–1307.
8. Jhaveri R. Live attenuated influenza vaccine: is past performance a guarantee of future results? *Clin Ther.* 2018;40:1246–1254.
9. Baker J, Jhaveri R. Conversations with the editors: promoting science and combating anti-science: the past and present of the antivaccine movement. *Clin Ther.* 2020;42:2248–2252.
10. Lindenfeld L, Jhaveri R. Conversations with the editors: promoting science and combating antisense: a focus on communication strategies. *Clin Ther.* 2020;42:2242–2247.
11. Ozer E, Kociolek LK, Jhaveri R. Conversations with the editors: the emergence of variants amid population-wide SARS-CoV-2 vaccination efforts: how much should we worry? *Clin Ther.* 2021;43:1630–1635.
12. Trooskin S, Jhaveri R. Conversations with the editors: hepatitis C virus—where are we now and where do we go from here? *Clin Ther.* 2020;42:1425–1432.
13. Bianchi DW, Maron JL. Conversations with the editors: the past, present, and future of placental research at the Eunice Kennedy Shriver National Institute of Child Health and Human Development. *Clin Ther.* 2021;43:211–217.
14. Stanford FC, Maron JL. Conversations with the editors: combating caregiver and patient-perceived obesity stigmatization. *Clin Ther.* 2021;43:1140–1146.
15. Jhaveri R, Maron JL. Our pledge to assemble a more diverse and inclusive editorial team at *Clinical Therapeutics*. *Clin Ther.* 2021;43 S0149-2918(21)00494-X.